Predictive factors for progression‐free survival in non‐small cell lung cancer patients receiving nivolumab based on performance status

Abstract

In patients with NSCLC treated with nivolumab, the factors found to be predictive of shorter PFS in patients with good PS were never smoking, high CRP, liver metastasis, pleural effusion, and steroid administration, whereas high ALI was predictive of longer PFS in patients with poor PS.